Competition-based CRISPR-dCas9 transcriptional control mechanisms and application of dCas9 biosensors for high-throughput, cell-based protease inhibitor screens
Name
anderson-daander-phd-be-2021-thesis.pdf
Description
Thesis PDF
Size
3.98 MB
Format
Adobe PDF
Checksum (MD5)
a27a07e50374b21713bb0855517896b9
Author(s)
Anderson, Daniel Allen
Advisor(s)
Voigt, Christopher A.
Date Issued
September 2021
Publisher
Massachusetts Institute of Technology
Abstract
Catalytically-dead Cas9 (dCas9) is a programmable transcription factor that can be targeted to promoters through the design of small guide RNAs (sgRNAs), where it can function as an activator or repressor. In Chapter 1 of this thesis, I outline the multitude of tools and applications that have been developed for dCas9 circuits. I then discuss the limitations and advantages of these systems and and outline some of the most promising opportunities for dCas9-based genetic circuits.
In Chapter 2, I devise, model, and implement a new-to-nature transcriptional control mechanism using dCas9. Natural promoters use overlapping binding sites as a mechanism for signal integration, where the binding of one transcription factor can augment the activity of another. Here, I implement this strategy in Escherichia coli using pairs of sgRNAs designed to repress and then derepress transcription through competitive binding. I demonstrate that this mechanism can control both transcriptional initiation and transcriptional elongation with over 30-fold dynamic range. This work characterizes and demonstrates a new genetic control modality that could be used to build analog circuits or to implement cis-regulatory logic on CRISPRi-targeted native genes.
In the final chapter of this thesis, I use a dCas9 genetic circuit to create an in vivo selection system for protease inhibitors. By leveraging a previously-described dCas9 toolkit, I create a synthetic genetic circuit that responds to SARS-CoV-2 viral protease activity. Using this circuit as an in vivo biosensor, I integrate it with a RiPP-based molecular library and an in vivo selection system to screen for inhibitors of the SARS-CoV-2 Papain-like protease (PLpro). With this integrated system, I screened tens of millions of RiPPs and identified DAA680, a 13-AA modified peptide with PLpro inhibitory activity. However, follow-up studies showed that this peptide also inhibits another SARS-CoV-2 viral protease, CLpro, indicating a non-specific mechanism of inhibition. Nonetheless, these results validate our system’s ability to identify and isolate RiPP-based protease inhibitors from large libraries. Additionally, our extensive characterization of the selection system should be generalizable to any biosensor with a transcriptional output. This should enable the rapid deployment of novel cell-based selection methods that can identify molecules with diverse bioactivities.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
In Copyright - Educational Use Permitted
Copyright MIT
Persistent DSpace Link
